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The C5a receptor has a key role in immune
complex glomerulonephritis in complement factor
H–deficient mice
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Chronic serum sickness leads to the formation of glomerular
immune complexes; however, C57BL/6 mice do not develop
glomerulonephritis unless complement factor H (CFH) is
absent from the plasma. Here we studied the role for C5a
receptor (R) in this setting. The exaggerated humoral
immune response in CFH/ mice was normalized in CFH/
C5aR/ double knockout mice, highlighting the C5aR
dependence. The CFH knockout mice developed proliferative
glomerulonephritis with endocapillary F4/80þ macrophage
infiltration, a process reduced in the double knockout mice.
There was no interstitial inflammation by histologic criteria
or flow cytometry for F4/80þLy6ChiCCR2hi inflammatory
macrophages. There were, however, more interstitial
CD3þCD4þ T lymphocytes in CFH knockout mice with
chronic serum sickness, while double knockout mice had
greater than 5-fold more Ly6CloCCR2lo anti-inflammatory
macrophages compared to the CFH knockout mice. Mice
lacking C5aR were significantly protected from functional
renal disease as assessed by blood urea nitrogen levels. Thus,
IgG- and iC3b-containing immune complexes are not
inflammatory in C57BL/6 mice. Yet when these mice lack CFH,
sufficient C3b persists in glomeruli to generate C5a and
activate C5aR.
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The complement system provides a first line of defense
against some microorganisms and participates in innate and
adaptive immune responses to many others. More than 30
plasma and cell-associated proteins in three activation
pathways converge on C3 and C5 to generate C3a, C3b,
C5a, and C5b-9, each of which has biological activity. The
C3a and C5a anaphylatoxins have specific rhodopsin family
seven-span transmembrane receptors (R). The three extra-
cellular loops of C3aR and C5aR confer ligand-binding
specificity, whereas their activation is transduced through
various abg G-proteins at the internal portion of the plasma
membrane.1,2 Although traditionally considered proinflam-
matory on bone marrow–derived cells, it is clear that C3aR
and C5aR have a more widespread distribution with a variety
of effects attributable to their activation.3,4
The ability to surmount infectious challenges is presumed
to have driven evolution of an active complement system.
This does appear to have its price, with diseases such as
atypical hemolytic uremic syndrome and age-related macular
degeneration attributable to mutations conferring gain of
function to activators and/or loss of function to regulators
within the complement system.5–7 A relatively proactivating
state of complement also appears relevant in a group of
human glomerular diseases with membranoproliferative
histopathological features and predominant C3 deposition,
collectively termed C3 glomerulopathy.8 To date, most
frequently implicated in these various diseases are genetic
abnormalities in the important fluid-phase complement
regulator, complement factor H (CFH).9,10
CFH is also an important complement regulator in mice;
CFH/ mice of mixed genetic background develop glomer-
ulonephritis (GN) spontaneously, which leads to the late
death ofB25% of mice.11,12 This GN occurring in 1-year-old
DBA/2 and C3H/HeN background CFH/ mice requires C5
but not C6.11,12 The genetic background is relevant, as C57BL/
6 mice appear resistant to GN occurring spontaneously in
CFH deficiency, as well as that occurring with immune
complex deposition in chronic serum sickness (CSS).13 In
contrast to wild-type C57BL/6 mice, C57BL/6 CFH/ mice
are uniformly susceptible to CSS with development of diffuse
proliferative GN.14
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Pharmacologically targeting the complement system is
now a clinical reality. Because of the nature of complement
activation, many inhibitors directed against a given comple-
ment protein also block successive steps in the activation
pathway(s). For example, the anti-C5 antibody eculizumab
prevents formation of C5a and C5b-9; the latter accounts for
its therapeutic efficacy and now is in routine clinical use in
paroxysmal nocturnal hemoglobinuria, as well as increased
risks of Neisserial infections.15 Eculizumab is highly effective,
but it is also the only complement inhibitor in clinical use.
Thus, it has been used in a number of past and present
clinical trials, including in membranous nephropathy, lupus
nephritis, atypical and Shiga toxin–associated hemolytic
uremic syndrome, C3GN, and anti-neutrophil autoanti-
body-mediated GN,16–18 diseases with a considerable range
in phenotype. Identifying which among the limited number
of active complement products are pathogenic in a given
disease process is not a trivial point. Blocking those that are
not directly relevant to the disease will needlessly impair
normal immunity and potential counterregulatory (anti-
inflammatory) signals, for which there is growing evidence.3
Here we addressed the role for C5aR in CSS-induced GN
occurring in CFH/ mice. Activation through C5aR appears
to have several effects in this model, the net of which is
necessary for disease.
RESULTS
C5aR-dependent acute kidney injury in CFH/mice with CSS
Here we used the CSS model induced with heterologous
(apo)ferritin as originally described by Stilmant et al.19 and
modified by Iskandar et al.20,21 C57BL/6 CFH/ and CFH/
C5aR/ mice (n¼ 14 each) were actively immunized with
daily intraperitoneal horse spleen apoferritin. As controls,
CFH/ (n¼ 4) and CFH/C5aR/ (n¼ 8) mice were
treated identically, except that apoferritin was omitted from
the injections. As shown in Figure 1, control CFH/ mice
had normal renal function at the end of the 5-week
experimental protocol as assessed by blood urea nitrogen
(BUN) levels. In contrast, CFH/ mice with CSS had
impaired renal function (BUN¼ 51.4±12.4mg/dl), which
was prevented in CFH/C5aR/ mice (BUN¼ 34.0
±8.9mg/dl; Po0.001 vs. CFH/ mice). Thus, functional
renal insufficiency in the CSS model requires both the absence
of CFH and the presence of C5aR.
C5aR dependence of renal inflammation in CFH/ mice with
CSS
Histopathological features of GN were evaluated at the end of
the 5-week experimental protocol. As in past studies,11,14
some control CFH/ mice had GN scores of 0.5–1.0, as was
also true of control CFH/C5aR/ mice (Figure 2a).
CFH/ mice with CSS developed GN, which was signifi-
cantly reduced in CFH/C5aR/ mice (Figure 2a and b;
P¼ 0.024). The primary histopathological feature was diffuse
hypercellularity of the glomerular tufts (Figure 2b). The
cellular composition of the observed GN was due, at least in
part, to F4/80þ monocytic cells (Figure 2c). Thus, endoca-
pillary diffuse proliferative GN in CSS appears to require
absent complement regulation from CFH allowing signals
through C5aR.
As typical for this model,14 there was no interstitial
nephritis by histopathological criteria.22 To evaluate whether
there were more subtle changes in mononuclear and
lymphocytic cell populations within the interstitium, a
separate group of animals was studied with CSS followed
by flow cytometry. F4/80þLy6Cþ cells in tissue sites are
considered macrophages, and can be divided by expression
levels of Ly6C and CCR2 into inflammatory M1 (Ly6-
ChiCCR2hi) and anti-inflammatory (or ‘alternative’) M2
(Ly6CloCCR2lo) macrophages.23–25 Saline-treated controls
had few Ly6ChiCCR2hi cells in kidneys, which was also true
for both groups of animals with CSS (Figure 3a and b).
CFH/C5aR/ mice with CSS had considerably increased
intrarenal Ly6CloCCR2lo cells relative to CFH/ control and
CSS groups (Figure 3a and b). Consistent with an M2
macrophage phenotype, these cells were CD115þF4/
80loCD11bþCD11clo as well; they were clearly distinct from
CD115F4/80hiCD11bþCD11cþ dendritic cells (Supple-
mentary Information online).
Peripheral blood F4/80þ cells from the same animals were
also studied. Control CFH/ mice receiving saline had
distinct Ly6CloCCR2lo and Ly6ChiCCR2hi populations (Figure
3b, right panel), allowing comparison with those in the kidney
(Figure 3b, left panel). Interestingly, both were reduced in
CFH/ mice with CSS, along with apparent shift of the
Ly6CloCCR2lo population toward higher expression of both
90
80
70
60
50
40
BU
N 
(m
g/d
l)
30
20
10
0
CFH –/– CFH –/–
*
CFH –/–C5aR –/– CFH –/–C5aR –/–
Saline Apoferritin
Figure 1 |C5aR-dependent impairment of renal function in
CFH/ mice with CSS. Blood urea nitrogen (BUN) levels were
measured after 5 weeks of active immunization of CFH/ and
CFH/C5aR/ mice with apoferritin or saline as controls. Data
from each group were normally distributed. Shown are individual
values from all mice studied, with the mean value in each group
as a horizontal line. Groups were significantly different by analysis
of variance (Po0.001). *Po0.001 vs. CFH/C5aR/ plus
apoferritin. CFH, complement factor H; CSS, chronic serum
sickness.
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Figure 2 |Chronic serum sickness (CSS) leads to C5aR-dependent glomerulonephritis (GN) with macrophage infiltration in
CFH/ mice. Histopathological features of disease were determined after 5 weeks of active immunization of CFH/ and CFH/
C5aR/ mice with apoferritin or saline as controls. (a) Semiquantitative GN scores from each mouse were compiled. Shown are individual
values from all mice studied. Groups were significantly different by Kruskal–Wallis testing (Po0.001). *P¼ 0.024 vs. CFH/C5aR/ plus
apoferritin. Representative periodic acid–Schiff staining (b) and immunofluorescence staining for F4/80þ cells (c) is shown for CFH/ and
CFH/C5aR/ mice with CSS. Original magnification,  400.
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Figure 3 |Role of C5aR in interstitial macrophage (a, b) and T lymphocyte (c) numbers in CFH/ mice after 5 weeks of active
immunization with apoferritin or saline as controls. The percentage of F4/80þ kidney cells that were Ly6ChiCCR2hi or Ly6CloCCR2lo is
shown graphically in a with representative flow cytometry histograms shown in b. Peripheral blood mononuclear cells were studied in
parallel, allowing comparisons with kidney cells. Representative data from kidney and blood are from the same animal. Similarly, the
percentage of total isolated kidney cells that were CD3þCD4þ or CD3þCD8þ was determined (there was no CD3þCD4þCD8þ
population; c). All log-transformed data were normally distributed and used in statistical analyses. Individual values from all mice studied are
shown (a, c), with y-axes as log scales and means as horizontal lines. All data are derived from the same pool of cells and are directly
comparable, whereas the y-axis scales were varied based on data. All groups but Ly6ChiCCR2hi cells had significantly different variances
by analysis of variance (Po0.015). Significant differences in follow-up statistical comparisons are shown individually. CFH, complement
factor H.
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Ly6C and CCR2. As occurred in kidneys, CFH/C5aR/
mice had fewer Ly6ChiCCR2hi cells, but greater numbers of
Ly6CloCCR2lo cells, than CFH/ mice with CSS.
The percentage of intrarenal CD19þ B lymphocytes tended
to be increased in CSS, with values of 9.6 (6.0–13.5), 14.8
(11.0–18.8), and 14.6 (13.1–23.5) in CFH/ controls, and
CFH/ and CFH/C5aR/ mice with CSS, respectively
(NS). Relative to controls, there were increased CD3þ T
lymphocytes in kidneys from CFH/mice with CSS, accounted
for by CD4þ cells (Figure 3c). In contrast, there was a decrease
in CD8þ cells only in kidneys of CFH/C5aR/ mice with
CSS (Figure 3c). Thus, infiltration with both CD3þCD4þ and
CD3þCD8þ T lymphocytes appears to have a C5aR
dependence in the CSS model, with both being lower in kidneys
of CFH/C5aR/ mice compared with CFH/ mice.
Effects of C5aR and altered humoral immune response on
renal disease in CFH/ mice with CSS
Glomeruli of CFH/ mice with CSS had immunoglobulin G
(IgG) within mesangial regions with some extension to
peripheral capillary walls, which was significantly reduced in
CFH/C5aR/ mice with CSS (stained red in Figure 4);
respective median staining scores were 3.0 (2.0–3.0) and 2.0
(1.5–2.5; Po0.015). As anticipated, glomeruli from CFH/
mice had linear glomerular capillary wall staining for C3
(stained green in Figure 4). As we have seen in prior
studies,14,26,27 the baseline bright C3 staining was reduced in
areas of IgG staining (Figure 4b, white arrows). Besides
immunofluorescence microscopy, our past studies have shown
that glomerular capillary wall complement regulation is
insufficient when plasma CFH is absent; this allows ongoing
C3 activation by immune complexes.26
In the 12 control mice receiving saline, measured anti-horse
apoferritin IgG levels were 0.1±0.03U/ml (all p0.3U/ml),
consistent with the specificity of the technique. Active
immunization did lead to generation of anti-apoferritin
antibodies, which were greater in actively immunized CFH/
mice compared with CFH/C5aR/ mice (5.3±0.1 and
3.9±0.1U/ml, respectively; Po0.001). Consistent with our
past studies,14 the anti-apoferritin humoral immune response
was exaggerated in CFH/ mice, as shown by comparison
with anti-apoferritin IgG levels of 3.5±0.2 U/ml in five
wild-type C57BL/6 mice studied as controls. Thus, excessive
production of anti-apoferritin IgG in CFH/ mice, which
we presumed to have a complement dependence, is
specifically C5aR dependent.
Measured anti-apoferritin IgG, glomerular IgG deposits,
GN scores, and BUN values were all decreased in CSS in
CFH/C5aR/ mice relative to CFH/ mice. We were
interested to determine whether these variables were related; in
particular, whether the observed effects of C5aR deficiency on
renal disease could be attributed to reduction of anti-
apoferritin IgG to wild-type levels. Glomerular IgG deposition
positively correlated with serum anti-apoferritin IgG (r¼ 0.46,
P¼ 0.013), with the two experimental groups being completely
distinct in this analysis (as shown by the box in Figure 5a).
Neither serum anti-apoferritin nor glomerular IgG had any
relation to GN scores (r¼ 0.27–0.37). BUN levels positively
correlated with both anti-apoferritin IgG values (Figure 5b;
r¼ 0.65, Po0.001) and the extent of GN (Figure 5c; r¼ 0.48,
P¼ 0.010). Each had an independent contribution to BUN
levels, as shown by the equation [BUN]¼6.2 þ 17.3 anti-
apoferritin/2 þ 6.5 GN (r¼ 0.72, Po0.001); even though
anti-apoferritin was weighted in half (to be comparable to GN
scores), it remained the principal determinant of BUN. Thus,
C5aR-dependent excessive production of anti-apoferritin IgG
antibodies in CFH/ mice tracks strongly with several end-
organ disease features.
DISCUSSION
There is a body of evidence supporting the relevance of
complement activation in immune complex GN.20,28,29 In the
experimental CSS model, C57BL/6 mice are completely
resistant to glomerular inflammation unless they lack CFH,
in which case they are uniformly susceptible to GN.14 This is
attributable to plasma-derived CFH facilitating inactivation
of C3b in glomerular-bound immune complexes, which
occurs even with large immune complex burdens.26 In these
instances, despite the abundance of IgG and iC3b in
glomeruli, which are respective ligands for inflammatory cell
FcgRs and b2-integrins, there is no glomerular inflammation.
Thus, inflammatory cell recruitment to glomeruli appears to
require an additional ‘signal;’ on the basis of considerable
circumstantial evidence, we felt this likely to be a comple-
ment activation product. Here we confirm this premise and
show that C5a acting through its cognate receptor C5aR is
required for this immune complex GN model.
The relevance of C5a generation and C5aR signaling in
acute glomerular neutrophil infiltration has been illustrated
by C5-dependent, C6-independent nephrotoxic serum ne-
phritis in CFH/ mice12 and C5aR-dependent experimental
anti-neutrophil autoantibody GN.30 Lipopolysaccharide is
a potent inducer of C5aR expression in a variety of cells
including those in the kidney,31,32 which is attributable to
CCAAT and CP2 sites in the C5aR promoter.33 Matsuo
colleagues34 administered lipopolysaccharide along with
nephrotoxic serum to generate a thrombotic microangio-
pathy model, which required complement activation and
signals through C5aR. This model has features in common
with experimental anti-phospholipid antibody syndrome, in
which complement activation led to C5aR-dependent
placental infiltration with neutrophils and subsequent fetal
loss.35 Here, CFH/ mice lacking C5aR had reduced
functional (i.e., BUN) and histopathological features of
GN. Compared with these acute models of passive antibody
administration, CSS is a relatively chronic disease process.
Thus, rather than neutrophils, C5aR signals were responsible
for endocapillary GN with infiltrating F4/80þ macrophages.
The CSS model is induced through repetitive immuniza-
tion with apoferritin alone (i.e., without adjuvant) to
generate an active humoral immune response. As in our
prior studies,14 CFH/ mice with CSS had increased serum
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levels of anti-apoferritin IgG compared with wild-type
controls. We can now attribute this to excessive generation
and signaling through C5aR, given equivalent anti-apoferri-
tin IgG titers among wild-type and CFH/C5aR/ mice. It
has become clear that C5aR signals can affect adaptive
immune responses in a variety of ways. C5aR can promote
Th1 responses in T cells36 and inhibit effects of interferon-g
in macrophages.37 Thus, Wenderfer et al.38 showed that
relative to control MRL/Faslpr lupus mice C5aR/MRL/
Faslpr mice had diminished production of interferon-g and
interleukin-12, reduced CD4þ T-cell responses, and 15-fold
less anti-double-stranded DNA IgG2a antibodies, together
with lessened glomerular endo- and extracapillary inflamma-
tion and protection from renal failure.
In CSS and MRL/Faslpr models of GN, antibodies to
exogenous or endogenous antigens are formed. These
generate complement-activating immune complexes that
deposit in glomeruli from the circulation and/or are formed
directly in situ. The fact that C3 and C4 are key in immune
complex processing is well established,39 including in these
two model systems.13,27,40 The potential relevance for C5aR
signals in glomerular immune complex processing in CSS
was supported by studies by Falk and Jennette,20 in which
C5-deficient mice had less glomerular immune complexes
independent from the anti-apoferritin IgG response. There
are also lower quantities of glomerular immune complexes in
C5aR-deficient MRL/Faslpr lupus mice compared with C5aR-
sufficient controls.38 Consistent with these two studies are
our findings that C5aR-deficient CFH/ mice had lower
serum anti-apoferritin and glomerular-deposited IgG, which
were independent from each other. An elegant paradigm
advanced and supported experimentally by Gessner and
colleagues41 is that C5aR activation of Gai2 and phosphoi-
nositide 3-kinase p110g in mononuclear phagocytes leads to
a transcriptional increase in FcgRIII and decrease in FcgRIIB
through respective gene promoter ‘C5a-inductive’ and ‘C5a-
suppressive’ regions.41–43 This phenomenon is relevant in
experimental disease models of liver, lung, and kidney (i.e.,
mesangial cells);44–46 clinically relevant is the fact that
blocking C5aR signals may underlie the therapeutic efficacy
of intravenous immunoglobulin.47 Thus, by altering the
balance between activating and inhibitory FcgRs on mono-
cytic cells, C5aR can have a considerable impact on immune
complex processing and its downstream effects.
In studies by Welch et al.48 using the CSS model, mice
given lipopolysaccharide contemporaneously developed
C5aR-dependent tubulointerstitial nephritis. Although CFH
is a critical glomerular capillary wall complement regulator, it
appears to be dispensable in the tubulointerstitium.49,50
Thus, in our studies described here, there was little interstitial
C3
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IgG
Figure 4 |Representative immunofluorescence staining for C3 (green) and immunoglobulin G (IgG, red) in glomeruli of CFH/
and CFH/C5aR/ mice with chronic serum sickness. (a) Linear glomerular capillary wall C3 staining typical for unmanipulated CFH/
mice was present in both groups. Mesangial IgG was present in both groups, but in greater relative amounts and with more extension to
the peripheral capillary wall in CFH/ mice compared with CFH/C5aR/ mice. (b) Individual staining for C3 and IgG are shown, along
with the merged image. The arrows depict regions with colocalized C3 and IgG. CFH, complement factor H.
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inflammation and few Ly6ChiCCR2hi (M1) macrophages in
all groups. The fact that CFH/ but not CFH/C5aR/
mice with CSS have increased interstitial CD3þCD4þ T
lymphocytes relative to controls illustrates that this occurs in
a C5aR-dependent manner, which is also true in MRL/Faslpr
lupus mice.38 The fate of interstitial CD3þCD8þ T
lymphocytes also appears to rely on C5aR, given that the
reduction occurs only in CFH/C5aR/ mice with CSS.
M2 macrophages are alternative to M1 macrophages, as they
tend to limit inflammation and promote repair within
tissues.23,24,51 There were considerably more Ly6CloCCR2lo
cells in the peripheral blood and renal interstitium of
CFH/C5aR/ mice with CSS, indicating a blocking effect
of signals through C5aR. Our ability to distinguish M1 from
M2 macrophages in glomeruli is limited; as best we can
determine based on F4/80 staining, glomerular inflammation
is due to M1 macrophages, whereas M2 macrophages are
restricted to the renal interstitium. Thus, although M2
macrophage numbers correlate with protection from clin-
icopathological features of GN in this model, their role(s) in
this disease is not clear. Theoretically, when complement
activation and C5aR signaling cease, the accumulation of M2
macrophages could be important in preserving renal function
in inflammatory diseases of the different renal compart-
ments.52–54
Taking the current data together with our past work,
glomeruli of wild-type C57BL/6 mice with CSS are normal
despite the presence of abundant IgG- and iC3b-containing
immune complexes. In the absence of plasma CFH, there can
be active C3b to form C5 convertases. These generate
sufficient quantities of C5a to provide necessary proinflam-
matory signals through C5aR to result in glomerular
inflammation and the clinicopathological picture of GN.
Downstream effects of C5aR include increasing FcgRIII
quantities43 and aMb2 integrin (complement receptor 3)
ligand avidity,55,56 allowing recognition of and activation by
IgG/iC3b-bearing immune complexes in the glomerulus. Our
data presented here suggest that the effects of C5aR in the
active inflammatory CSS model extend beyond promoting
glomerular infiltration with F4/80þ macrophages. Dissecting
the individual effects of C5aR signals on immune and
inflammatory responses, and how each impacts renal disease,
does have its experimental impediments; in particular, cells of
both afferent and efferent immune systems originate from
bone marrow stem cells, making chimeric studies proble-
matic. Our ongoing research is attempting to surmount these
obstacles.
MATERIALS AND METHODS
Animals
CFH/ and C5aR/ mice were generated and kindly provided by
Drs Matthew Pickering and Marina Botto (Imperial College of
London)11 and Drs Allison Humbles and Craig Gerard (Harvard
Medical School),57 respectively. Animals were backcrossed at least
10 generations onto normal C57BL/6 mice (Jackson Laboratories,
Bar Harbor, ME). Genotyping within and around CFH and C5aR
alleles was performed using PCR-based approaches. All studies were
approved by the University of Chicago Institutional Animal Care
and Use Committee.
Two separate sets of experiments were performed with a total of 63
mice equally divided between CFH/ (n¼ 31) and CFH/C5aR/
(n¼ 32) groups. Male mice at 8 weeks of age were studied. In each
experiment, littermate animals of comparable ages were studied. CSS
was induced with daily intraperitoneal administration of 4mg horse
spleen apoferritin (Calzyme Laboratories, San Luis Obispo,
CA).14,19–21 Controls (n¼ 8 from each group) were treated identically,
except that apoferritin was omitted from the saline vehicle. After 5
weeks, animals were killed, and blood and tissues were collected.
BUN concentrations were measured with a Beckman Autoanalyzer
(Fullerton, CA).
Measurements from renal tissue
Tissues were fixed in 10% buffered formalin and embedded in
paraffin, from which 4-mm-thick sections were cut and stained with
periodic acid–Schiff. Slides were scored in a blinded manner by a
renal pathologist (AC) for the extent of GN and interstitial nephritis
using scales of 0 to 4 (in increments of 0.5) according to the schema
of Passwell et al.22 as described previously.14,26
Sections (4mm) from frozen mouse kidneys were fixed in
ethanol/ether (1:1) for 10min followed by 95% ethanol for 20min,
washed with phosphate-buffered saline, and stained with fluorescein
anti-mouse C3 and rhodamine anti-mouse IgG (Cappel, MP
Biomedicals, Solon, OH). For staining with Alexa 488 anti-mouse
F4/80 (AbD Serotec, Raleigh, NC), sections were fixed twice with
cold acetone (10min, 4 1C) with intervening air-drying. Slides were
viewed with an Olympus BX-60 IF microscope (Carter Valley, PA).
Representative photomicrographs were taken at identical settings
with a Hamamatsu EM-CCD camera (Bridgewater, NJ).
Renal-infiltrating cells and peripheral blood mononuclear cells
were isolated as described previously.58 In brief, mouse kidneys were
minced and digested at 37 1C for 25min with gentle agitation with
collagenase I (2mg/ml) and DNAse I (100mg/ml) in Hank’s
buffered salt solution/1% (vol/vol) bovine serum albumin (all from
Sigma/Aldrich, St Louis, MO). Erythrocytes were lysed with NH4Cl,
and the cell suspension was passed through a 40-mm cell strainer
(BD Biosciences, Franklin Lakes, NJ). Isolated cells (B106) from
each mouse kidney and peripheral blood were blocked with mAb
24.G2 and stained with monoclonal antibodies (with labeled fluor in
parentheses) to CD3 (brilliant violet), F4/80 (PE/Cy7), Ly6C (Alexa
488) (Biolegend, San Diego, CA), CD4 (fluorescein isothiocyanate),
CD8 (allophycocyanin) (AbDSerotec), and CCR2 (phycoerythrin)
(RnD Systems, Minneapolis, MN). Flow cytometry was performed
with a BD Biosciences LSR II and analyzed with the FlowJo software
(Tree Star, Ashland, OR).
Statistical methods
Data were analyzed using the Minitab statistical software (v. 16,
College Park, MD). Data sets were first analyzed with the
Anderson–Darling normality test and considered parametric with
Ha40.05. Data from flow cytometry were log-transformed.
Parametric and nonparametric data are presented as mean±s.e.m.
and median (Q1–Q3), respectively. All data presented graphically are
from individual animals. Parametric data were analyzed by one-way
analysis of variance with comparisons among groups using Fisher’s
method. Nonparametric data sets were analyzed comparably by
Kruskal–Wallis and Mann–Whitney testing. Potential correlations
966 Kidney International (2012) 82, 961–968
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among variables were first examined by calculating the Pearson
product moment; those significant were further examined using the
least-squares method.
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